Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

ŽÁČKOVÁ, D.; SEMERÁD, L.; FABER, E.; KLAMOVÁ, H.; STEJSKAL, L.; BĚLOHLÁVKOVÁ, P.; KARAS, M.; CMUNT, E.; ČERNÁ, O.; PROCHÁZKOVÁ, J.; ČIČÁTKOVÁ, P.; KVETKOVÁ, A.; HORŇÁK, T.; SKOUMALOVÁ, I.; SRBOVÁ, D.; ŠÁLEK, C.; BUFFA, D.; VOGLOVÁ, J.; JURČEK, T.; FOLTA, A.; JEŽÍŠKOVÁ, I.; ŽIŽKOVÁ, H.; MACHOVÁ POLÁKOVÁ, K.; ET AL. Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF. Leukemia. 2024, vol. 38, no. 4, s. 893-897. ISSN 0887-6924. SJR: 3.376, rok: 2022; Cite Score: 17.100, rok: 2022; IF: 11.400, rok: 2022.